Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil: Southwest Oncology Group Study 9024

Journal of Urology

Volumn 176, Issue 2, 2006, Pages 548-553

  Swanson, Gregory P ^a   Faulkner, James ^b,d   Smalley, Stephen R ^e   Noble, Mark J ^f   Stephens, Ronald L ^e   O'Rourke, Timothy J ^a,b,c,d,e,f   Weiss, Geoffrey R ^a   Quick, Donald P ^c   Thompson Jr , Ian M ^a   Crawford, E David ^g  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c Department of Orthopaedic Surgery   (United States)

^d SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^e Kansas City Community Clinical Oncology Program   (United States)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

chemotherapy; fluorouracil; prostate; prostatic neoplasms; radiotherapy

Indexed keywords

FLUOROURACIL; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; PYRIDOXINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; DIARRHEA; DOSE RESPONSE; EDEMA; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN TISSUE; INCIDENCE; LYMPH NODE METASTASIS; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BIOPSY; WEIGHT REDUCTION;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33745459180     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.03.068     Document Type: Article

References (21)

1. Perez C.A., Hanks G.E., Leibel S.A., Zeitman A.L., Fuks Z., and Lee W.R. Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. Cancer 72 (1993) 3156
2. Perez C.A., Lee H.K., Georgiou A., Logsdon M.D., Lai P.P., and Lockett M.A. Technical and tumor-related factors affecting outcome of definitive irradiation for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 26 (1993) 581
3. Bagshaw M.A., Cox R.S., and Ray G.R. Status of radiation treatment of prostate cancer at Stanford University. (NCI Monographs). Mongr Natl Ca Inst 7 (1988) 47
4. Kuban D.A., el-Mahdi A.M., and Schellhammer P.F. Potential benefit of improved local tumor control in patients with prostate carcinoma. Cancer 75 (1995) 2373
5. Zagars G.K., Pollack A., and von Eschenbach A.C. Prostate cancer and radiation therapy-the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 33 (1995) 23
6. Swanson G.P., Riggs M.W., and Earle J.D. Long term follow-up of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 406
7. Falkson G., and Falkson H.C. Fluorouracil and radiotherapy in gastrointestinal cancer. Lancet 2 (1969) 1252
8. Smalley S.R., Kimler B.F., and Evans R.G. 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys 20 (1991) 207
9. Smalley S.R., Kimler B.F., Evans R.G., and Dalziel W.C. Heterogeneity of 5-Flurouracil radiosensitivity modulation in cultured mammalian cell lines. Int J Radiat Oncol Biol Phys 18 (1990) 184
10. Green S., and Weiss G.R. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs 10 (1992) 239
11. Zeitman A.L., Coen J.J., Dallow K.C., and Shipley W.U. The treatment of prostate cancer by conventional radiation therapy. an analysis of long-term outcome. Int J Radiat Oncol Biol Phys 32 (1995) 287
12. Cox J.D., and Kline R.W. Do prostate biopsies 12 months or more after external irradiation for adenocarcinoma, stage III, predict long term survival?. Int J Radiat Oncol Biol Phys 9 (1983) 299
13. Bagshaw M.A. Current conflicts in the management of prostate cancer. Int J Radiat Oncol Biol Phys 12 (1986) 1721
14. Crook J., Malone S., Perry G., Bahadur Y., Robertson S., and Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 48 (2000) 355
15. Pilepich M.V., Winter K., Murray K., John M.J., Suase W., Rubin P., et al. Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of he prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243
16. Lawton C.A., Winter K., Murray K., Machtay M., Mesic J.B., Hanks G.E., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) Trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int Jrl Radiat Oncol Biol Phys 49 (2001) 937
17. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study). phase III randomized trial. Lancet 360 (2002) 103
18. Ryan C.J., Zelefsky M.J., Heller G., et al. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high risk localized prostate cancer. Urology 64 (2004) 90
19. Kumar P., Perrotti M., Weiss R., Todd M., Goodin S., Cummings K., et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol 22 (2004) 1909
20. Petrylak D.P., Tangen C.M., Hussain M.H., Lara Jr. P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513
21. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502